Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?
- 17 September 2021
- journal article
- other
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (43), 4418-4419
- https://doi.org/10.1093/eurheartj/ehab673
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- The Evolving Post-PCI Antithrombotic TherapiesThe New England Journal of Medicine, 2021
- Dual Antiplatelet Therapy after PCI in Patients at High Bleeding RiskThe New England Journal of Medicine, 2021
- Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled TrialJournal of the American College of Cardiology, 2021
- Applying Decision Analysis to Inform the US Food and Drug Administration’s Benefit–Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMISPublished by Ovid Technologies (Wolters Kluwer Health) ,2021
- Ticagrelor in Patients with Stable Coronary Disease and DiabetesThe New England Journal of Medicine, 2019
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCIJAMA, 2019
- Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trialThe Lancet, 2018
- 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationPolish Heart Journal, 2018
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal, 2017